title: Clinical appraisal of tafluprost in the reduction of elevated intraocular pressure (IOP) in open-angle glaucoma and ocular hypertension.
abstract: An elevated intraocular pressure (IOP) is one of the most important risk factors for the development of glaucoma, which causes progressive optic neuropathy. Lowering IOP is currently the only therapeutic approach to the treatment of glaucoma. Tafluprost, a novel prostaglandin analogue, was recently launched onto the market as an ocular hypotensive agent. Tafluprost is potent in its affinity for the prostanoid FP receptor and in its intraocular lowering efficacy. Moreover, it enhances the ocular hemodynamics and has neuroprotective effects. Clinical studies have demonstrated its efficacy at decreasing intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
authors.affiliation: Department of Ophthalmology, University of Tokyo School of Medicine, Tokyo, Japan. aihara-tky@umin.net
authors.forename: Makoto
authors.initials: M
authors.lastname: Aihara
references.citation: J Ocul Pharmacol Ther. 2008 Oct;24(5):521-6
references.pmid: 18808364
references.citation: Acta Ophthalmol Suppl (Oxf ). 2008;242:14-9
references.pmid: 18752510
references.citation: Br J Pharmacol. 2008 Jul;154(5):1079-93
references.pmid: 18587449
references.citation: Ophthalmology. 2004 Sep;111(9):1641-8
references.pmid: 15350316
references.citation: Invest Ophthalmol Vis Sci. 2005 Nov;46(11):4159-63
references.pmid: 16249494
references.citation: Exp Eye Res. 2004 Apr;78(4):767-76
references.pmid: 15037111
references.citation: Exp Eye Res. 2008 Sep;87(3):251-6
references.pmid: 18602392
references.citation: Surv Ophthalmol. 2001 May;45 Suppl 4:S337-45
references.pmid: 11434936
references.citation: Acta Ophthalmol Suppl (Oxf ). 2008;242:7-13
references.pmid: 18752509
references.citation: J Ocul Pharmacol Ther. 2003 Dec;19(6):501-15
references.pmid: 14733708
references.citation: Graefes Arch Clin Exp Ophthalmol. 2009 Oct;247(10):1353-60
references.pmid: 19551401
references.citation: Ophthalmology. 2005 Oct;112(10):1661-9
references.pmid: 16111758
references.citation: J Ocul Pharmacol Ther. 2007 Aug;23(4):359-65
references.pmid: 17803434
references.citation: Drug Metab Dispos. 2009 Aug;37(8):1622-34
references.pmid: 19477946
references.citation: Int J Clin Pharmacol Ther. 2008 Aug;46(8):400-6
references.pmid: 18793581
references.citation: Br J Ophthalmol. 2007 May;91(5):673-6
references.pmid: 17124244
references.citation: Eur J Ophthalmol. 2009 Mar-Apr;19(2):214-22
references.pmid: 19253237